+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evolving use of new oral anticoagulants for treatment of venous thromboembolism



Evolving use of new oral anticoagulants for treatment of venous thromboembolism



Blood 124(7): 1020-1028



The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the majority of patients with venous thromboembolism (VTE). With a rapid onset of action and the capacity to be administered in fixed doses without routine coagulation monitoring, NOACs streamline VTE treatment. In phase 3 trials in patients with acute symptomatic VTE, NOACs have been shown to be noninferior to conventional anticoagulant therapy for prevention of recurrence and are associated with less bleeding. Rivaroxaban and dabigatran are already licensed for VTE treatment in the United States, and apixaban and edoxaban are under regulatory consideration for this indication. As the number of approved drugs increases, clinicians will need to choose the right anticoagulant for the right VTE patient. To help with this decision, this review (1) compares the pharmacologic profiles of the NOACs, (2) outlines the unique design features of the phase 3 trials that evaluated the NOACs for VTE treatment, (3) reviews the results of these trials highlighting similarities and differences in the findings, (4) provides perspective about which VTE patients should receive conventional treatment or are candidates for NOACs, and (5) offers suggestions about how to choose among the NOACs.

(PDF emailed within 0-6 h: $19.90)

Accession: 053107410

Download citation: RISBibTeXText

PMID: 24923298

DOI: 10.1182/blood-2014-03-563056


Related references

New oral anticoagulants for treatment of venous thromboembolism. Deutsche Medizinische Wochenschrift 136(22): 1162-1164, 2011

New oral anticoagulants for the treatment of venous thromboembolism. Best Practice and Research. Clinical Haematology 26(2): 151-161, 2014

New oral anticoagulants for the treatment ofA venous thromboembolism. 2013

Oral anticoagulants for the treatment of venous thromboembolism. Bailliere's Clinical Haematology 11(3): 639-661, 1999

New oral anticoagulants in the treatment of venous thromboembolism. Presse Medicale 42(9 Pt 1): 1232-1238, 2013

Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 20(5): 490-500, 2016

The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. Expert Opinion on PharmacoTherapy 16(16): 2391-2394, 2016

Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. Hematology/Oncology Clinics of North America 30(5): 1035-1051, 2017

Management of oral anticoagulants in the treatment of venous thromboembolism. European Journal of Internal Medicine 12(2): 75-85, 2001

Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. Cardiovascular and Hematological Disorders Drug Targets 15(2): 92-96, 2016

Direct oral anticoagulants for venous thromboembolism treatment and prophylaxis. Jaapa 29(8): 24-29, 2018

Treatment of venous thromboembolism in the era of non-vitamin K antagonist oral anticoagulants. Journal of the Medical Association of Thailand 98 Suppl 1: S111-S117, 2015

Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. Seminars in Thrombosis and Hemostasis 41(2): 160-165, 2015

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan. Journal of Atherosclerosis and Thrombosis 24(6): 560-565, 2017

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. Hamostaseologie 37(4): 241-255, 2017